Biowarfare applications of a new immunoregulator

新型免疫调节剂的生物战应用

• 批准号: 6689861
• 负责人: KENNETH O WILLEFORD
• 金额: $ 13.36万
• 依托单位: GENEBACT BIOTECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-08-01 至 2004-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6689861
• 关键词: antibacterial agents; antiviral agents; bacterial disease; bacterial vaccines; bioassay; biological response modifiers; bioterrorism /chemical warfare; blood lipoprotein; drug design /synthesis /production; drug discovery /isolation; drug preservation; drug screening /evaluation; immunologic memory; immunomodulators; laboratory mouse; laboratory rat; pathologic process; scintillation counter; viral vaccines; virus diseases

DESCRIPTION (provided by applicant): If biological weapons were to be used by a terrorist organization, the public health system would be overwhelmed. The ease of use and delivery along with the apparent widespread availability of biological weapon grade agents could inflict mass civilian casualties anywhere in the world. The best way to combat and defend bioterrorism is to be prepared. Scientists at GeneBact Biotechnologies, Inc. have discovered a new class of Biological Response Modifiers from mammalian serum that we refer to as the Immune Cell Proliferation Factors ("ICPF"). ICPFs are novel lipoproteins that have been shown to have no direct antimicrobial activity, yet retain their ability to abate microbial pathogenesis as presented in a Salmonella typhimurium mouse model and a Pasteurella multocida avian model. ICPFs also show no direct virucidal activity, yet retain the ability to abate viral pathogenesis as presented in a West Nile Virus mouse model and a Parvovirus rat model. ICPFs were also shown to significantly increase levels of the circulating antibodies to Parvovirus in vaccinated rats when the vaccine was adjuvanted with ICPF as compared to a non-adjuvanted vaccine control. The primary objectives of this project are to (i) establish the safety and efficacy of an ICPF formulation for broad spectrum human use in the treatment of bacteremias and viremias, (ii) evaluate the efficacy of an ICPF formulation to provide prophylactic and therapeutic protection against both bacterial and viral infectious agents, and (iii) evaluate the efficacy of ICPF as and adjuvant in vaccines to amplify and expand existing stores of vaccines. The secondary objective of this project is to evaluate the "immunological memory" conferred upon infected patients treated with ICPF. Accomplishing the Tasks as outlined will provide specific benefits to address biowarfare issues in three major areas: 1. Provide a short-term prophylactic agent for use in high-risk populations such as military personnel entering a biological warfare theater of war. 2. Provide an effective therapeutic agent for personnel exposed to a biological warfare agent. 3. Provide an adjuvant to expand and amplify the existing stockpiles of vaccines.

描述（由申请人提供）：如果恐怖组织要使用生物武器，则公共卫生系统将不知所措。易于使用和交付，以及显而易见的生物武器级代理商的广泛可用性可能会造成世界上任何地方的大规模平民伤亡。战斗和捍卫生物恐怖主义的最佳方法是准备。 Genebact Biotechnologies，Inc。的科学家已经发现了一种新的生物学反应修饰剂，我们将其称为免疫细胞增殖因子（“ ICPF”）。 ICPF是新型的脂蛋白，已证明没有直接的抗菌活性，但保留了在鼠伤寒小鼠鼠伤寒小鼠模型中介绍的减轻微生物发病机理的能力和紫外病的紫外病鸟类模型。 ICPF也没有直接的病毒活性，但保留了在西尼罗河病毒小鼠模型和细小病毒大鼠模型中介绍的减轻病毒发病机理的能力。与非辅助疫苗对照相比，当疫苗佐剂辅助疫苗时，ICPF还显示出接种疫苗的大鼠循环抗体水平。该项目的主要目的是（i）建立ICPF公式的安全性和功效，以在人类治疗细菌和病毒蛋白酶中的广泛使用中使用，（ii）评估ICPF配方的疗效，以提供预防和治疗性，以提供对细菌和病毒感染的敏感性和（ICII）的影响，并评估ICPF和ICPF的效果，以及ICPF的效果，以及ICPF的效果，并促进ICPF的效果。扩展现有疫苗的现有存储。该项目的次要目标是评估赋予用ICPF治疗的感染患者的“免疫记忆”。完成概述的任务将提供特定的好处，以解决三个主要领域的生物处理问题：1。提供短期预防代理人，用于在高风险人群中使用，例如进入生物战剧院的军事人员。 2。为暴露于生物战代理的人员提供有效的治疗剂。 3。提供佐剂，以扩大和扩增现有的疫苗库存。